Literature-reported formulation composition
Component: Iso-A11B5C1 | mol%: 60 | Role: Ionizable lipid
sales@dcchemicals.com
Iso-A11B5C1
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DOPE | mol%: 10 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | mol%: 29 | Role: Sterol
Literature-reported formulation composition
Component: C14-PEG2000 (14:0 PEG2000 PE) | mol%: 1 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 100 | Role: Source values retained
Reported observation
Literature-reported Apparent LNP pKa 7.21 Post-formulation characterization · SM-102 LNP approximately 6.7 Main Figure 3B and text, PNAS p. 5
Reported observation
Literature-reported Muscle FLuc expression Comparable to the SM-102 benchmark at the injection site 6 h after 0.3 mg/kg IM mLuc · No statistically significant difference versus SM-102 Main Figure 2D,E and text, PNAS p. 4
Reported observation
Literature-reported Off-target reporter expression No measurable expression in examined off-target organs 6 h after 0.3 mg/kg IM mLuc · SM-102 produced high liver and spleen expression Main Figure 2D,E and text, PNAS p. 4
Reported observation
Literature-reported Physical biodistribution Cy5-mRNA signal localized primarily at the injection site with minimal liver or spleen transfer 6 h after 0.3 mg/kg IM Cy5-mLuc · SM-102 showed broader injection-site, liver and spleen distribution Main Figure 2F,G and text, PNAS p. 4
Reported observation
Localized Cre-mRNA gene editing Iso-A11B5C1 and SM-102 produced comparable editing at the injected quadriceps. SM-102 produced 83.83% liver and 72.67% spleen editing, whereas editing in those tissues was undetectable with iso-A11B5C1 in the reported experiment. Cre mRNA; mTmG reporter mice; 0.5 mg/kg IM; 36 h · Main Figure 3C-E and text, PNAS p. 5
Reported observation
Cell-type selectivity in vitro Relative to SM-102 LNP, iso-A11B5C1 LNP showed 42-fold higher transfection in HeLa cells but 28-fold and 24-fold lower transfection in HepG2 cells and splenocytes, respectively. mLuc LNP; HeLa, HepG2 and primary splenocyte comparison · Main Figure 3A and text, PNAS p. 4
Reported observation
Melanoma mRNA-vaccine study Iso-A11B5C1 LNP carrying full-length Trp2 mRNA significantly slowed B16-F10-Luc tumor growth and outperformed the MC3 comparator; it also increased IFN-gamma-positive CD8 T cells and intratumoral CD8 T-cell infiltration versus MC3. The authors reported lower efficacy than the SM-102 group. C57BL/6 melanoma model; two LNP/mTrp2 doses on days 7 and 12 after inoculation; dose not reported · Main Figure 5 and text, PNAS p. 7
Reported observation
Reported acute inflammatory profile Four hours after IM dosing, the measured GM-CSF, IFN-gamma, IL-1alpha, IL-5, IL-6 and TNF-alpha levels did not differ discernibly between iso-A11B5C1-treated and PBS-treated mice. BALB/c mice; 0.5 mg/kg IM; acute cytokine assessment at 4 h · Supplementary Figure S8 and main text, PNAS p. 5